PCSK9 inhibitors drugs

Sep 08, 2025

The Unmet Need in Cholesterol Management Cardiovascular Diseases (CVDs) continue to be one of the leading causes of morbidity and mortality worldwide, primarily driven by underlying lipid disorders, including Hypercholesterolemia (familial and non-familial hypercholesterolemia), Dyslipidemia, Atherosclerotic Car...

Oct 10, 2022

Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...